553 related articles for article (PubMed ID: 20533453)
1. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
2. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
3. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
4. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
5. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
6. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
7. Anticancer platinum (IV) prodrugs with novel modes of activity.
Chin CF; Wong DY; Jothibasu R; Ang WH
Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
[TBL] [Abstract][Full Text] [Related]
8. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate.
Bouvet D; Michalowicz A; Crauste-Manciet S; Brossard D; Provost K
Inorg Chem; 2006 Apr; 45(8):3393-8. PubMed ID: 16602799
[TBL] [Abstract][Full Text] [Related]
9. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
11. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
12. Polymeric drug delivery of platinum-based anticancer agents.
Haxton KJ; Burt HM
J Pharm Sci; 2009 Jul; 98(7):2299-316. PubMed ID: 19009590
[TBL] [Abstract][Full Text] [Related]
13. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
14. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
15. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
[TBL] [Abstract][Full Text] [Related]
16. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
18. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
19. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
20. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Yang J; Liu W; Sui M; Tang J; Shen Y
Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]